ASCOT is the largest study of hypertension ever undertaken in Europe involving >19,000 patients and also includes the study of lipid management in >10,000 patients. The results of ASCOT have had a significant impact on the prevention of coronary heart disease (CHD) and other vascular events by lowering blood pressure and reducing cholesterol. This further updated and expanded version provides clinicians with a comprehensive and detailed review of the final results of ASCOT by the steering committee of the trial. Additionally, the authors discuss implications of ASCOT for daily practice.
Preface 1: The history of a trial 2: Hypertension trial review - ASCOT in context 3: ASCOT blood pressure-lowering arm (ASCOT-BPLA): methods, results and impact 4: ASCOT sub-studies 5: ASCOT - cardiovascular benefits in subjects with diabetes 6: New-onset diabetes and impact of glycaemia on cardiovascular events 7: Multiple risk factor intervention: evidence of benefits from ASCOT 8: Combination therapy 9: Health economic review 10: Potential synergy between CCBs and ACE inhibitors 11: Guidelines practice and future projects